Oura's $900M AI Bet: Tracking the Flow to $1B Revenue

The company's financial scale is now backed by a massive capital infusion. Oura raised over $900 million in a new Series E round, valuing the company at $11 billion. The round was led by Fidelity Management & Research Company, with participation from ICONIQ and other investors, underscoring the market's confidence in its growth trajectory.

This funding directly supports its aggressive sales target. The company reported revenue of over $500 million in 2024 and expects to reach $1 billion in sales in 2025. This doubling of revenue from the prior year is built on explosive product adoption, with nearly 3 million of the 5.5 million rings sold since 2015 occurring in 2025 alone.

The capital will accelerate that growth, specifically to advance its AI strategy. Oura plans to use the funds to accelerate AI and product innovation and expand global distribution. This move from a consumer wellness device to a platform for preventive health is now backed by the liquidity needed to scale its AI-powered Advisor and new health features.

The AI Model: A $19B Market Play

The model is a direct bet on a massive, growing market. The global women's health app market is valued at $4.30 billion in 2025 and is projected to expand to approximately $19.88 billion by 2034, growing at an 18.7% compound annual rate. This trajectory represents a clear, high-growth opportunity for a platform like Oura.

Oura is launching its proprietary large language model as its entry point. The new AI, rolling out in its experimental hub Oura Labs, is designed to deliver personalized insights across the full reproductive spectrum. It integrates biometric data from the ring with a knowledge base of clinician-curated medical standards and research, aiming to provide guidance on menstrual health, fertility, and menopause.

This mechanism creates a potential upsell driver within the subscription ecosystem. By offering deeper, more personalized health insights powered by its own AI, Oura can increase user engagement and justify premium tiers. The model's focus on women-a segment identified as its fastest-growing user group-aligns it directly with the market's largest and most dynamic segment.

Catalysts, Risks, and What to Watch

The success of Oura's AI bet hinges on user adoption. The new model is currently rolling out in Oura Labs, the company's opt-in, experimental feature hub. For the AI to refine its insights and deliver value, a significant portion of its active user base must participate. This opt-in flow is the first critical data point to watch, as it will determine the quality and scale of the personalized health data the model can learn from.

Regulatory risk is a looming overhang. The FDA's Office of Women's Health (OWH) sets the Agency's research agenda and funds projects related to sex differences in medicine. As Oura's AI moves from general wellness to providing specific health guidance, it may attract increased scrutiny. The evolving regulatory landscape for AI in healthcare, compounded by recent shifts in judicial deference to agencies like the FDA, creates uncertainty for deployment timelines and feature scope.

On the competitive front, Oura is actively fortifying its market position. The company recently won its initial patent lawsuit against competitors Ultrahuman and RingConn, resulting in a ruling that could stop them from importing smart rings into the U.S. by October 2025. This legal victory, if upheld, would limit hardware competition and protect Oura's share of the wearable market, providing a crucial moat for its AI platform to grow within a captive user base.